Company intelligence / Profile preview

Sanarus Technologies

Pleasanton, California, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Sanarus Technologies has developed the Visica 2 cryoablation system, which is FDA-cleared and commercially available as a minimally invasive alternative to surgery for treating benign breast tumors such as fibroadenomas. The device is also in Phase 2 clinical trials for the treatment of malignant breast cancer. Thousands of successful cases have been reported with high patient satisfaction rates (~97%). Clinical results show promise in both safety and efficacy.

Therapeutic areas: OncologyWomen's Health
Modalities: Device (specifically cryoablation technology)
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Sanarus Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanarus Technologies.

Explore the full profile